Revenues for the quarter fell 4.4% to $11,488 million, missing the Zacks Consensus Estimate of $11,672 million. Revenues were hit by the patent expiry of Singulair (indicated for the chronic treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback